Abemaciclib

Composition:

Each film-coated tablet contains Abemaciclib……………………50mg.

Indication:

LuciAbe is a kinase inhibitor indicated:

• In combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence.
• In combination with an aromatase inhibitor as initial endocrinebased therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
• In combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine theray.
  •As monotherapy for the treatment of adult patients with HRpositive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.

Dosage and Use:

LuciAbe tablets are taken orally with or without food.

• Recommended starting dose in combination with fulvestrant, tamoxifen, or an aromatase inhibitor: 150 mg twice daily.
• Recommended starting dose as monotherapy: 200 mg twice daily.
• Dosing interruption and/or dose reductions may be required based on individual safety and tolerability.